Darvocet was a prescription painkiller used to treat mild to moderate pain. It combined two active ingredients: propoxyphene, a weak opioid, and acetaminophen (the same ingredient in Tylenol). The drug was pulled from the U.S. market in November 2010 after clinical evidence linked it to fatal heart rhythm problems, and it is no longer available anywhere in the world.
What Darvocet Was Prescribed For
Darvocet was designed for everyday pain that was too persistent for over-the-counter options but not severe enough to warrant stronger opioids like oxycodone or morphine. Doctors commonly prescribed it for dental pain, headaches, musculoskeletal injuries, menstrual cramps, and post-surgical discomfort. It sat on the lower end of the opioid ladder, intended as a step up from plain acetaminophen or ibuprofen.
The drug came in two strengths. Darvocet-N 50 contained 50 mg of propoxyphene and 325 mg of acetaminophen, while Darvocet-N 100 contained 100 mg of propoxyphene and 650 mg of acetaminophen. The idea behind combining the two ingredients was straightforward: propoxyphene blocked pain signals in the brain while acetaminophen worked through a separate, still not fully understood pathway to reduce pain and fever. Clinical trials in patients with postpartum pain confirmed that the combination provided more relief than either ingredient alone.
How Darvocet Worked
Propoxyphene is classified as a centrally acting opioid, meaning it attaches to opioid receptors in the brain and spinal cord to dull pain perception. It was structurally related to methadone but far weaker. In practice, many clinicians considered its pain-relieving power only marginally better than acetaminophen by itself, which fueled debate about whether the added risks of an opioid were worth it.
The acetaminophen component reduced pain and lowered fever through a mechanism that, even today, isn’t completely mapped out. Together, the two drugs were meant to offer broader pain coverage than either one could deliver on its own.
Why Darvocet Was Removed From the Market
Darvocet had a troubled safety record long before its final withdrawal. The drug was originally approved for worldwide use in 1957, but concerns about overdose deaths, addiction potential, and a dangerously narrow margin between a therapeutic dose and a toxic one accumulated over decades.
The UK’s medicines regulator began phasing out propoxyphene-containing drugs in 2005. The European Medicines Agency followed in 2009. In November 2010, new clinical data showed that propoxyphene caused dose-related changes to the heart’s electrical activity, even at normal prescribed doses. These changes increased the risk of serious, potentially fatal heart rhythm abnormalities. The FDA requested that all manufacturers voluntarily pull propoxyphene products from the U.S. market. Taiwan followed in March 2011.
Before the withdrawal, propoxyphene had already been linked to high rates of emergency department visits, poisoning deaths (particularly when combined with alcohol or other sedatives), and suicides. The drug’s extremely narrow therapeutic index meant the difference between a dose that relieved pain and a dose that caused cardiac toxicity was uncomfortably small.
Risks That Led to the Ban
The cardiac risk was the final straw, but it wasn’t the only problem. Propoxyphene carried the same risks as other opioids: physical dependence, tolerance (needing higher doses over time for the same effect), and addiction. Because Darvocet was perceived as a “mild” painkiller, patients and prescribers sometimes underestimated these dangers.
The acetaminophen component added its own risk. At high doses or with long-term use, acetaminophen can cause severe liver damage. Patients who took Darvocet alongside other acetaminophen-containing products, sometimes without realizing it, could easily exceed safe limits. Combining Darvocet with alcohol magnified both the liver risk from acetaminophen and the sedation and respiratory depression from propoxyphene.
What Replaced Darvocet
No single drug stepped in as a direct replacement. Instead, the approach to mild-to-moderate pain has shifted significantly since 2010. Current guidelines from the CDC emphasize maximizing non-opioid options first because they don’t carry the same risks as opioids.
For acute pain from injuries, dental procedures, or surgery, the first-line options are now over-the-counter or prescription-strength NSAIDs (like ibuprofen or naproxen) and acetaminophen. These two classes of pain relievers work through different pathways and can be taken together for stronger relief without opioid side effects.
For chronic or recurring pain, the toolkit is broader. Physical therapy and structured exercise programs are now considered central to treatment, not just add-ons. Certain antidepressants that also dampen pain signaling are effective for nerve pain and musculoskeletal conditions. Anti-seizure medications like gabapentin serve a similar role for nerve-related pain. Topical options, including medicated patches and anti-inflammatory creams applied directly to the painful area, avoid many of the systemic side effects of pills. Psychological approaches like cognitive behavioral therapy help patients manage chronic pain by changing how the brain processes pain signals.
When these options aren’t enough, doctors may still prescribe opioids for short-term use, but the conversation around those prescriptions has changed dramatically. The emphasis is on the lowest effective dose for the shortest necessary time, a sharp contrast to the era when Darvocet was handed out freely for routine aches and pains.
If You Still Have Darvocet at Home
Because the drug has been off the market for over a decade, any remaining pills are well past their expiration date. Expired propoxyphene can degrade into compounds that are even more toxic than the original drug. If you find old Darvocet in a medicine cabinet, take it to a pharmacy or a local drug take-back program for safe disposal rather than flushing it or throwing it in the trash.